Uncovering the genetically-driven differential susceptibility to chronic obstructive pulmonary disease and pulmonary fibrosis
Overview
Organization: National Heart, Lung, and Blood Institute
Start Date: 12/2022
End Date: Ongoing
Primary Goal: Goal 4: Increase and sustain research to better understand the prevention, pathogenesis, diagnosis, treatment, and management of COPD.
Secondary Goal(s):
Objective(s):
- Help expand, coordinate, and optimize COPD research efforts
Collaboration: Brigham and Women's Hospital
Activity Type: Research
Activity Description
Chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF) are two devastating chronic lung diseases with distinct clinical features, which may be due to genetic differences. In fact, there are at least five regions of the genome (loci) where the genetic variants that increase the risk of developing COPD decrease the risk of developing IPF. We plan to characterize how these “COPD/IPF opposite risk loci” contribute to gene expression changes in specific lung cells, which will give us new knowledge about the biology of COPD and IPF, both of which are lacking effective therapies.Audience
General Audience: Researchers
Focused Audience: n/a
Program Reach: National
Type of Area: N/A
Setting: Workplace
Cost and Funding Sources
It was funded through the National Heart, Lung, and Blood Institute and funds to be allotted to grantees.Impact Analysis
Results of their programs are in progress.Advice or Lessons Learned
In process.Contact Information
National Heart, Lung, and Blood Institute
Program Analyst
Bethesda
Maryland